Exosomes can be used as vehicles to deliver therapeutic siRNAs, which specifically target the mutant form of KRAS, to the pancreas inhibiting the action of this oncogene. About 70% of patients with pancreatic cancer harbour mutations in the gene KRAS. Exosomes carrying siRNA contain at their surface the CD47 protein, the "don't eat me" signal that allows the exosomes to bypass the clearance by the immune system.
